IRF8 polyclonal Antibody | BS7865

IRF8 polyclonal Antibody | BS7865 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Application: WB IF

Application Range: WB 1:500 - 1:2000 IF 1:50 - 1:200

Background: ICSBP (Interferon (IFN) consensus sequence-binding protein, Interferon regulatory factor 8; IRF-8) is a transcription factor that is important for IFN-γ-mediated signaling during dendritic cell and macrophage differentiation. ICSBP physically interacts with TRAF6 (between amino acid residues 356 and 305), and this interaction of ICSBP with TRAF6 modulates TLR signaling and may contribute to the cross-talk between IFN-γ and TLR signal pathways. ICSBP antagonizes Bcr/Abl by downregulation of Bcl-2. ICSBP is known to interact with chromatin, and bind PU.1 in macrophages. ICSBP belongs to the IFN regulatory factor (IRF) family that also includes IRF-1, IRF-2, and ISGF-3. These proteins are composed of a conserved DNA-binding domain in the N-terminal region and a divergent C-terminal region that serves as the regulatory domain. The IRF family proteins bind to the IFN-stimulated response element (ISRE) and regulate expression of IFN-α and IFN-β.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: IRF8 polyclonal Antibody detects endogenous levels of IRF8 protein.

Molecular Weight: ~ 47 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: H ICSBP; H-ICSBP; HGNC:5358; HGNC5358; HICSBP; ICSBP 1; ICSBP; ICSBP1; ICSBP1; Interferon Consensus Sequence Binding Protein 1; Interferon consensus sequence binding protein; Interferon consensus sequence-binding protein; Interferon Regulatory Factor 8; IRF 8; IRF-8; IRF8; IRF8; IRF8_HUMAN; MYLS;

Immunogen: Recombinant full length Human IRF8.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Contribution of Soluble Factors to EMT,